Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Renz

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 14, 2026
Corrigendum to "EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors" [Biomed. Pharmacother. 192 (2025), 118704]Bernhard Haller, Günther Hs Richter, Marco Wachtel, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.
Targeted Oncology|August 18, 2023
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center MunichDanmei Zhang, Klara Dorman, Kathrin Heinrich, et al.
Journal of Cancer Research and Clinical Oncology|July 7, 2022
Lessons learned: the first consecutive 1000 patients of the CCCMunich<sup>LMU</sup> Molecular Tumor BoardKathrin Heinrich, Lisa Miller-Phillips, Frank Ziemann, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 14, 2026
Corrigendum to "EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors" [Biomed. Pharmacother. 192 (2025), 118704]Bernhard Haller, Günther Hs Richter, Marco Wachtel, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.
Targeted Oncology|August 18, 2023
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center MunichDanmei Zhang, Klara Dorman, Kathrin Heinrich, et al.
Journal of Cancer Research and Clinical Oncology|July 7, 2022
Lessons learned: the first consecutive 1000 patients of the CCCMunich<sup>LMU</sup> Molecular Tumor BoardKathrin Heinrich, Lisa Miller-Phillips, Frank Ziemann, et al.
Pageof 3